Obesity is associated with a cluster of abnormalities, including hypertension, insulin
resistance, hyperinsulinemia, and elevated levels of both plasminogen activator inhibitor 1 …

Plasminogen activator inhibitor 1 (PAI-1) is likely to play a role in vascular disease, primarily
in subjects with android obesity. It has been demonstrated that PAI-1 is overexpressed in …

Plasma levels of type 1 plasminogen activator inhibitor (PAI-1), a risk factor for
cardiovascular disease, are elevated in obese subjects, especially those with omental fat …

Plasma plasminogen activator inhibitor 1 (PAI-1) levels are elevated in insulin-resistant
subjects and are associated with increased cardiovascular risk of atherothrombosis. Strong …

Human adipose tissue has been shown to produce plasminogen activator inhibitor type 1
(PAI-1). However, the importance of adipose tissue in the regulation of the PAI-1 plasma …

Among the list of coronary risk factors, it has recently been proposed that fibrinolytic system
impairment, due to increased plasminogen activator inhibitor-1 (PAI-1) levels in plasma …

Urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA)
play important roles in fibrinolysis, cell migration, tissue destruction, angiogenesis and tissue …

This study was aimed at evaluating the relationship between visceral fat accumulation and
plasma plasminogen activator inhibitor-1 (PAI-1) levels in healthy, obese men and women …

Purpose: Plasma levels of plasminogen activator inhibitor-1 are increased in obesity,
hypertension, and diabetes. Their correlation with insulin levels supports the hypothesis that …

This review addresses a continuum of the role of derangements in the fibrinolytic system
from the blood to the vessel wall in the pathogenesis of acute coronary events and the …